Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved NovaBay Pharmaceuticals's investigational new drug application to begin human clinical trials of its lead aganocide compound, NVC-422, for the prevention of catheter-associated urinary tract infections.
Subscribe to our email newsletter
Ron Najafi, chairman and CEO of NovaBay, said: “We are very pleased to have received rapid clearance of this important investigational new drug application (IND), as this enables us to stay on track with our clinical development programs and targeted milestones. Our current plans are to move NVC-422 into clinical trials for additional indications during 2008 through both our internal programs and those of our partner, Alcon.”